A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting.
BACKGROUND
Anginal chest pain without creatine kinase (CK) elevation is frequently observed in the first hours after coronary stenting. Possible causes of ischemic episodes are microembolism, side branch occlusion, coronary vasospasm, and disturbances of microvascular circulation. In a prospective, double-blind, randomized trial, we tested the effect of intravenous nitroglycerin on the incidence of angina and minor myocardial necrosis (MMN), as detected by cardiac troponin I increase, after elective coronary stenting.


RESULTS
One hundred patients were randomly assigned to intravenous nitroglycerin (group A: n = 50, goal dose 100 microgram/min) or placebo (group B: n = 50, NaCl 0.9%) during 12 hours after stenting. Patients with acute myocardial infarction, known intolerance to nitrates, and hemodynamic instability during angioplasty were excluded. The 2 groups were comparable in respect to baseline and interventional variables, except for age (group A: 60 +/- 9 years, group B: 56 +/- 10 years; P =.04). The incidence of chest pain was not influenced by nitroglycerin (group A: 18%, group B: 22%; P = not significant). However, the occurrence of MMN was significantly reduced by nitroglycerin (group A: 5%, group B: 19%, P =.036). A rise in CK with significant CK-MB fraction was observed in only 2 patients in group B (both less than twice upper limit). Only 4 of the 10 patients with MMN also had chest pain.


CONCLUSIONS
Routine use of intravenous nitroglycerin after coronary stenting significantly reduced the occurrence of minor myocardial necrosis. However, the incidence of postprocedural chest pain remained unchanged.
Kurz
D J
DJ
Division of Cardiology, Department of Internal Medicine, Triemli Hospital, Zurich, Switzerland. mkurz@opht.unizh.ch
Naegeli
B
B
Bertel
O
O
D000787:Angina Pectoris / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy; D004311:Double-Blind Method; D005260:Female; D006083:Graft Occlusion, Vascular / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D005996:Nitroglycerin / Q000008:administration & dosage*; D010149:Postoperative Pain / Q000097:blood / Q000000981:diagnostic imaging / Q000517:prevention & control*; D011446:Prospective Studies; D015607:Stents; D019210:Troponin I / Q000097:blood; D014665:Vasodilator Agents / Q000008:administration & dosage*
D015415:Biomarkers; D019210:Troponin I; D014665:Vasodilator Agents; D005996:Nitroglycerin